engleski

Possibilities for use of extracorporeal magnetic innervation in the treatment of chronic pelvic pain syndrome in males

Extracorporeal magnetic innervation (ExMI) is based on the principle described by Faraday's Law of Magnetic Induction. ExMI technology works by producing a highly focused, time-varying magnetic field that penetrates deep into the perineum, innervating the pelvic floor muscles by activating motor neurons. Pulses of steep gradient magnetic flux are produced by the therapy head placed inside the treatment chair. These fields penetrate the patient's perineum, initiate nerve impulses thus normalizing perineum muscles tonus and increasing their strength and endurance. NeoContol® is a complete pelvic floor therapy system that uses ExMI technology. NeoControl® was cleared by the U.S. Food and Drug Administration (FDA) in June of 1998 for the treatment of stress, urge and mixed incontinence in women. It is used in around fifty countries worldwide. The treatment of urinary incontinence in women with NeoControl® device is available in Croatia and is covered by the Croatian Institute for Health Insurance. The therapy is conduced in an out-patient department and patients remain in their clothes throughout the procedure. It is a non-invasive completely painless procedure with no known side effects. A cycle consists of 16-20 treatments, two times per 20 minutes weekly for 8-10 weeks. Contraindications for the use of ExMI are pregnancy, cardiac pacemaker, heart arrhythmias, metal implants, therapeutic pumps and intrauterine device. Numerous published papers confirm the efficiency and safety of ExMI in the treatment of patients with stress and urge incontinence. Chronic pelvic pain syndrome (CPPS) in males is a condition of unknown etiology and often with unsatisfactory treatment outcome. One hypothesis connects it with muscle dysfunction and/or nervous hypersensitivity and inflammation according to which neuromuscular pelvic spasm is the primary cause of symptoms. Some hypotheses, however, relate CPPS with present yet undetected infection, autoimmune diseases or sterile urine reflux. Adopting the hypothesis on neuromuscular spasm, we shall investigate the efficacy of ExMI in the treatment of patients with CPPS. Urologist E. Rowe and his colleagues from Great Britain performed a research (2005) on a small number of patients, proving the efficacy of ExMI. This gave us an incite to conduct a similar research on a larger number of patients. In our examinees with CPPS, we shall primarily exclude patients with infection, autoimmune disease and anatomical abnormality of the urogenital tract. The research will be conducted after we obtain approval from the Central Ethics Committee, and first results are expected to be available in 6 months.

*

nije evidentirano